Antibody-mediated rejection: treatment alternatives and outcomes

Transplantation Reviews

Volumn 23, Issue 1, 2009, Pages 34-46

  Singh, Neeraj ^a   Pirsch, John ^a   Samaniego, Millie ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALLOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CARIMUNE NF; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; GAMMAGARD LIQUID; GAMMAGARD SD; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IVEEGAM EN; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYGAM SD; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ANAPHYLAXIS; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BACKACHE; BLOOD CLOTTING; BONE MARROW SUPPRESSION; CENTRAL RETINA VEIN THROMBOSIS; CEREBROVASCULAR ACCIDENT; CHILL; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; DESENSITIZATION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEVER; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG EMBOLISM; MYALGIA; MYCOSIS; NAUSEA; NEOPLASM; OUTCOME ASSESSMENT; PLASMAPHERESIS; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; VIRUS INFECTION;

EID: 56249138952     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2008.08.004     Document Type: Article

References (134)

1. Montgomery R.A., Hardy M.A., Jordan S.C., et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 7 (2004) 181-185
2. Takemoto S.K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004) 1033-1041
3. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria-an addition to the Banff'97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708-714
4. Crespo M., Pascual M., Tolkoff-Rubin N., et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 71 (2001) 652-658
5. Rocha P.N., Butterly D.W., Greenberg A., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (2003) 1490-1495
6. Shah A., Nadasdy T., Arend L., et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77 (2004) 1399-1405
7. Pascual M., Saidman S., Tolkoff-Rubin N., et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66 (1998) 1460-1464
8. Tanabe K., Takahashi K., Sonda K., et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 65 (1998) 224-228
9. Jordan S.C., Vo A., Bunnapradist S., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
10. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3 (2003) 1017-1023
11. Gloor J.M., Lager D.J., Moore S.B., et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 75 (2003) 971-977
12. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
13. Schweitzer E.J., Wilson J.S., Fernandez-Vina M., et al. A high panel reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplatation 70 (2000) 1531-1536
14. Terasaki P. Humoral theory of transplantation. Am J Transplant 3 (2003) 665-673
15. Patel R., and Terasaki P. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
16. Jeannet M., Pinn V.W., Flax M.H., Winn H.J., and Russell P. Humoral antibodies in renal allotransplantation in man. N Engl J Med 282 (1970) 111-117
17. Terasaki P., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 (2004) 438-443
18. Hourmant M., Cesbron-Gautier A., Terasaki P., et al. Frequency and clinical implications of development of donor-specific and non-donor specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16 (2005) 2804-2812
19. Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74 (2002) 1192-1194
20. Mauiyyedi S., Della Pelle P., Saidman S., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12 (2001) 574-582
21. Solez K., Colvin R.B., Racusen L.C., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 7 (2007) 518-526
22. Ozawa M., Terasaki P.I., Lee J.H., et al. 14th International HLA and Immunogenetics Workshop: report on the prospective chronic rejection project. Tissue Antigens 69 Suppl 1 (2007) 174-179
23. Bohmig G.A., Exner M., Habicht A., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13 (2002) 1091-1099
24. Racusen L.C., Solez K., Colvin R.B., Bonsib S.M., Castro M.C., Cavallo T., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713-723
25. Theruvath T.P., Saidman S., Mauiyyedi S., et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 72 (2001) 77-83
26. Takahashi K., Takahara S., Uchida K., Oshima S., Toma H., and Sonoda T. Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan. Transplant Proc 34 (2002) 1604-1605
27. Akalin E., Ames S., Sehgal V., et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 76 (2003) 1444-1447
28. Sawada T., Fuchinoue S., and Teraoka S. Successful A1-to O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double filtration plasmapheresis. Transplantation 74 (2002) 1207-1210
29. Woodle E.S., Newell K.A., Haas M., et al. Reversal of accelerated renal allograft rejection with FK506. Clin Transplant 11 (1997) 251-254
30. Burke G.W., Colona J., Noto T., et al. Removal of pre-formed cytotoxic antibody using Prosorba (Staph Protein-A-Silica) column without immunosuppression. Transplant Proc 29 (1997) 2249-2251
31. Warren D.S., Zachary A.A., Sonnenday C.J., et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 4 (2004) 561-568
32. Madan A.K., Slakey D.P., Becker A., et al. Treatment of antibody-mediated accelerated rejection using plasmapheresis. J Clin Apheresis 15 (2000) 180-183
33. Gloor J.M., Lager D.J., Fidler M.E., et al. A comparison of splenectomy versus intensive post-transplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 80 (2005) 1572-1577
34. Nojima M., Yoshimoto T., Nakao A., et al. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation. Transplant Proc 37 (2005) 930-933
35. Jordan S.C., Quartel A.W., Czer L.S.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (1998) 800-805
36. Jordan S.C., Vo A.A., Tyan D., Nast C.C., and Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplantation 9 (2005) 408-415
37. Becker Y.T., Becker B.N., Pirsch J.D., and Sollinger H. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4 (2004) 996-1001
38. Montgomery R.A., Simpkins C.E., Zachary A.A., et al. Anti-CD20 rescue therapy for kidneys undergoing antibody-mediated rejection. Am J Transplant 4 Suppl 8 (2004) 258
39. Samaniego M., Zachary A.A., Lucas D., et al. Early allograft outcomes in patients with antibody mediated rejection treated with rituximab: a single center experience. Am J Transplant 2 Suppl 3 (2002) 259
40. Montgomery R.A., Cooper M., Kraus E., Rabb H., Samaniego M., and Simpkins C.E. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transplant (2003) 199-213
41. Abbas A.K., and Lichtman A.H. Cellular and molecular immunology. 5th ed. (2003), Saunders, Philadelphia (Pa)
42. Bonnefoy-Berard N., Vincent C., and Revillard J. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51 (1991) 669-673
43. Bonnefoy-Berard N., and Revillard J. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15 (1996) 435-442
44. Zand M.S., Vo T., Huggins J., et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79 (2005) 1507-1515
45. Zand M.S., Vo T., Pellegrin T., et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107 (2006) 2895-2903
46. Ayuk F.A., Fang L., Fehse B., Zander A.R., and Kroger N. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 33 (2005) 1531-1536
47. Kayler L.K., Farber J.L., Colombe B., LaCave D., Friedewald J.J., and Ratner L. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation. Transpl Int 19 (2006) 128-139
48. Allison A.C., and Engui E. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
49. Ishida H., Tanabe K., Furusawa M., Ishikuza T., Shimmura H., Tokumoto T., et al. Mycophenolate mofetil suppresses the production of anti-blood type antibodies after renal transplantation across the ABO blood barrier: ELISA to detect humoral activity. Transplantation 74 (2002) 1187-1189
50. Tanaka H., Tsugawa K., Nakahata T., Kudo M., Suzuki K., and Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol 63 (2005) 417-422
51. Liu D., Kobayashi T., Nagasaka T., et al. Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transpl Int 18 (2005) 401-407
52. Breedveld F.C., and Dayer J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59 (2000) 841-849
53. Saunders R.N., Metcalfe M.S., and Nicholson M. Rapamycin in transplantation: a review of the evidence. Kidney Int 59 (2001) 3-16
54. Wicker L.S., Boltz Jr. R.C., Matt V., Nichols E.A., Peterson L.B., and Sigal N. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 20 (1990) 2277-2283
55. Aagaard-Tillery K.M., and Jelinek D. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 156 (1994) 493-507
56. Corales R., Chua J., Mawhorter S., et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon. Transpl Infect Dis 2 (2000) 133-139
57. Yip N.H., Lederer D.J., Kawut S.M., et al. Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med 173 (2006) 917-921
58. Glynne R., Akkaraju S., Healy J.I., Rayner J., Goodnow C.C., and Mack D. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature 403 (2000) 672-676
59. Stevens C., Lempert N., and Freed B. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. Transplantation 51 (1991) 1240-1244
60. Yamaoka K., Kim K.M., Ishigami T., et al. Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells. Immunol Lett 36 (1993) 203-208
61. Morikawa K., Oseko F., and Morikawa S. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. Transplantation 54 (1992) 1025-1030
62. Kawamura H., Matsumura M., Kishi Y., et al. Double filtration plasmapheresis in an ABO-incompatible renal transplantation: a case report. Transplant Proc 35 (2003) 227-229
63. Bohmig G.A., Regele H., Exner M., et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 12 (2001) 2482-2489
64. Tyden G., Kumlien G., and Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76 (2003) 730-743
65. Yang K.S., Kenpe K., Yamaji K., Tsuda H., and Hashimoto H. Plasma adsorption in critical care. Ther Apher 6 (2002) 184-188
66. Shepherd J.C., Subramanian A., Montgomery R.A., et al. West Nile Virus encephalitis in a kidney transplant recipient. Am J Transplant (2004) 1-4
67. Gjorstrup P., and Watt R. Therapeutic protein A immunoadsorption. A review. Transfusion Science 11 (1990) 281-302
68. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfusion Med 11 (2001) 325-342
69. Bohmig G.A., Regele H., Saemann M.D., et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. Am J Kidney Dis 35 (2000) 667-673
70. Falson D.T., LaValley M.P., Baldassare A.R., et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 3 (1999) 240-245
71. Wiesenhuter C., Irish B., and Bertram J. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immnoadsorption column: a pilot trial. J Rheumatol 21 (1994) 804-812
72. Lennertz A., Fertmann J., Thomae R., et al. Plamapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases. Ther Apher & Dial 7 (2003) 529-535
73. Liu M., Ji S.M., Tang Z.H., et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. Transplant Proc 36 (2004) 2101-2103
74. Jordan S.C., Cunningham-Rundles C., and McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety and cost implications. Am J Transplant 3 (2003) 653-664
75. Gelfand E. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol 108 Suppl 4 (2001) s111-s116
76. Yu Z., and Lennon V. Mechanisms of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340 (1999) 227-228
77. Kazatchkine M.D., and Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
78. Semple J.W., Kim M., Lazarus A.H., and Freedman J. Gamma-globulins prepared form sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood 100 (2002) 1055-1059
79. Watanabe J., and Scornik J. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 5 (2005) 2786-2790
80. Sapir T., and Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29 (2005) 185-199
81. Jordan S.C., Vo A.A., Peng A., Toyoda M., and Tyan D. Intravenous Gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 (2006) 459-466
82. Wassmuth R., Hauser I.A., Schuler K., et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 71 (2001) 1436-1442
83. Cunningham-Rundles C., Zhou Z., Mankarious S., and Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 13 (1993) 272-278
84. Itkin Y.M., and Trujillo T. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 25 (2005) 886-892
85. Daphnis E., Stylianou K., Alexandrakis M., et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 106 (2007) 143-148
86. Cantu T.G., Hoehn-Saric E.W., Burgess K.M., Racusen L., and Scheel P. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 25 (1995) 228-234
87. Montgomery R.A., and Zachary A. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplantation 8 (2004) 535-542
88. Jordan S.C., Vo A., Nast C., et al. A four year follow-up of rejection patterns, treatment and outcomes in highly-HLA sensitized crossmatch positive patients transplanted with IVIg desensitization (Abstract). Am J Transplant 4 (2004) 256
89. Jordan S.C., and Pescovitz M.D. Presensitization: the problem and its management. Clin J Am Soc Nephrol 1 (2006) 421-432
90. Locke J.E., Zachary A.A., Haas M., et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7 (2007) 842-846
91. Kaplan B., Gangemi A., Thielke J., Oberholzer J., Sankary H., and Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 83 (2007) 99-100
92. Haas M., Rahman M.H., Racusen L.C., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 6 (2006) 1829-1840
93. Haas M., Montgomery R.A., Segev D.L., et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 7 (2007) 576-585
94. Gloor J.M., Sethi S., Stegall M.D., et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 7 (2007) 2124-2132
95. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and DeGoey S. A comparison of plasmapheresis versus high-dose IVIg desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
96. Tedder T.F., Zhou L.J., and Bell P.D. The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 14 D (1990) 195
97. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict responses to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
98. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
99. Voso M.T., Pantel G., Rutella S., et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 87 (2002) 918-925
100. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc-gamma-R IIIa gene. Blood 99 (2002) 754-758
101. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
102. Treon S.P., Mitsiades C., Mitsiades N., et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 24 (2001) 263
103. Cerny T., Borisch B., Introna M., Johnson P., and Rose A. Mechanism of action of rituximab. Anticancer Drugs 13 Suppl 2 (2002) S3-S10
104. Sonnenday C.J., Warren D.S., Cooper M., et al. Plasmapheresis, CMV Hyperimmune Globulin and anti-CD20 allow ABO-incompatible renal transplantatio without splenectomy. Am J Transplant 4 (2004) 1315-1322
105. Tyden G., Kumlien G., Genberg H., Sandberg J., Lundgren T., and Fehrman I. ABO kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5 (2005) 145-148
106. Peng A., Vo A., Bunnapradist S., Toyoda M., and Jordan S. Incidence and outcomes of treatment protocols for antibody-mediated rejection in highly sensitized patients transplanted using desensitization therapy. (Abstract). Am J Transplant and Transplantation World Transplant Congress 2006 (2006) 259
107. Melcher M.L., Olson J.L., Baxter-Lowe L.A., Stock P.G., and Posselt M. Antibody-mediated rejection of a pancreas allograft. Am J Transplant 6 (2006) 423-428
108. Garrett Jr. H.E., Groshart K., Duvall-Seaman D., Combs D., and Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 74 (2002) 1240-1242
109. Baran D.A., Lubitz S., Alvi S., et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc 36 (2004) 3164-3166
110. Faguer S., Kamar N., Guilbeaud-Frugier C., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83 (2007) 1277-1280
111. Vo A.A., Wechsler E., Jagolino J., et al. Monitoring for infectious complications of Campath 1H and Rituxan induction therapy in crossmatch positive kidney transplant patients receiving intravenous gammaglobulin desensitization (Abstract). Am J Transplant and Transplantation WTC supplement (2006) 122
112. Calame K. Plasma cells: finding new light at the end of B cell development. Nature Immunol 2 (2001) 1103-1108
113. Shapiro-Shelef M., and Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 16 (2004) 226-234
114. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2377-2386
115. Sidner R.A., Book B.K., Agarwal A., Bearden C.M., Vieira C.A., and Pescovitz M. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 13 (2004) 55-62
116. Gonzalez-Stawinski G.V., Yu P.B., Love S.D., Parker W., and Davis R.J. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98 (2001) 175-179
117. Nishio M., Fujimoto K., Yamamoto S., et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 137 (2007) 349-354
118. Shortt J., and Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 38 (2006) 433-436
119. Imashuku S., Teramura T., Morimoto A., Naya M., and Kuroda H. Prolonged hypogammaglobulinemia following rituximab treatment for post-transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 33 (2004) 129-130
120. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics and pharmacokinetics. Transplantation 77 (2004) 542-548
121. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6 (2000) 443-446
122. Nimmerjahn F., and Ravetch J. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
123. Basse G., Ribes D., Kamar N., et al. Rituximab therapy for the novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80 (2005) 1560-1564
124. Ruggenenti P., Chiurchiu C., Brusegan V., et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14 (2003) 1851-1857
125. Remuzzi G., Chiurchiu C., bate M., Brusegan V., Bontempelli M., and Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360 (2002) 923-924
126. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., and Moutsopoulos H. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
127. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 (2005) 540-548
128. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
129. Ghijsels E., Lerut E., Vanrenterghem Y., and Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43 (2004) e34-e38
130. Dudley C., Pohanka E., Riad H., et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 79 (2005) 466-475
131. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., and Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63 (1997) 39-47
132. Fulton B., and Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51 (1996) 278-298
133. Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 (2004) 2715-2729
134. Schwarz C., Regele H., Huttary N., et al. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Wien Klin Wochenschr 118 (2006) 397-404